Mariani G, Iacopino G, Pasquali-Lasagni R
Department of Human Biopathology, University of Rome La Sapienza, Italy.
Int J Clin Lab Res. 1992;22(2):111-4. doi: 10.1007/BF02591407.
The generation of thrombin was estimated by an assay for fibrinopeptide A which was developed and employed to evaluate the relationship between factor VII and thrombin release. The amount of fibrinopeptide A released correlated strongly, when assayed in the early stages of the reaction, with factor VII coagulant activity levels in the range 50-2,000 units/dl. The method was then applied to study the relationship between factor VII and fibrinopeptide A in plasma from blood donors, women on the pill and patients on oral anticoagulants (with a range of factor VII coagulant activity from 8.5 to 600 units/dl). The overall evaluation of the relationship between factor VII and fibrinopeptide A showed a strong correlation which was higher for factor VII coagulant activity (r = 0.90) than for factor VII antigen levels (r = 0.817). The regression analysis which best fitted the data was the multiplicative one, indicating that thrombin formation increases faster when factor VII coagulant activity is in the upper part of the normal range or higher. In patients on oral anticoagulants, the correlation between factor VII and fibrinopeptide A was very poor. Our data fit well with the findings of the epidemiological studies in which high levels of factor VII coagulant activity were shown to be associated with an increased incidence of fatal coronary artery disease.
通过一种纤维蛋白肽A检测法来估算凝血酶的生成，该检测法已被开发并用于评估因子VII与凝血酶释放之间的关系。在反应早期进行检测时，释放的纤维蛋白肽A的量与50 - 2000单位/分升范围内的因子VII凝血活性水平密切相关。然后该方法被应用于研究献血者、服用避孕药的女性以及口服抗凝剂患者（因子VII凝血活性范围为8.5至600单位/分升）血浆中因子VII与纤维蛋白肽A之间的关系。因子VII与纤维蛋白肽A之间关系的总体评估显示出很强的相关性，因子VII凝血活性的相关性（r = 0.90）高于因子VII抗原水平的相关性（r = 0.817）。最符合数据的回归分析是乘法回归分析，表明当因子VII凝血活性处于正常范围上限或更高时，凝血酶形成的增加更快。在口服抗凝剂的患者中，因子VII与纤维蛋白肽A之间的相关性非常差。我们的数据与流行病学研究结果非常吻合，在这些研究中，高水平的因子VII凝血活性被证明与致命性冠状动脉疾病的发病率增加有关。
